Austin Shandley, PA
Physician Assistant · Kansas City, MONPI 1881085066
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,419 of the $11,085 with a category attached, or 75.9%. 26 manufacturers reported payments, led by Johnson & Johnson at 27.5% of the total. 2025 is the largest year on record at $3,238, 2.6 times the $1,245 reported in 2021. Among physician assistant clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AbbVie$973
- UCB, Inc.$750
- Sun Pharmaceutical Industries Inc.$742
- E.r. Squibb & Sons, L.L.C.$710
- Sanofi$692
- plus $4K from 20 others
Across 8 payments — averaging $174.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$1,95018%
- Travel & lodging$360%
- Food & beverage$8,41976%
- Education$6806%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 58 | $3,054 |
| AbbVie | 66 | $973 |
| UCB, Inc. | 30 | $750 |
| Sun Pharmaceutical Industries Inc. | 41 | $742 |
| E.r. Squibb & Sons, L.L.C. | 45 | $710 |
| Sanofi | 22 | $692 |
| Lilly USA, LLC | 34 | $646 |
| Novartis | 27 | $645 |
| Amgen | 29 | $588 |
| Regeneron Healthcare Solutions, Inc. | 16 | $434 |
| Almirall LLC | 3 | $343 |
| Galderma Laboratories, L.p. | 10 | $248 |
| Incyte Corporation | 10 | $228 |
| LEO Pharma Inc. | 4 | $203 |
| Journey Medical Corporation | 3 | $191 |
| Sanofi-aventis U.S. LLC | 2 | $169 |
| Pfizer | 5 | $77 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $70 |
| Mayne Pharma Commercial LLC | 4 | $67 |
| Dermavant Sciences, Inc. | 3 | $55 |
| Genentech USA, Inc. | 7 | $55 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| Bristol Myers Squibb | 1 | $40 |
| Arcutis Biotherapeutics, Inc. | 1 | $24 |
| Organon | 3 | $21 |
| Botanix SB Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,085 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 21 | $285,196 |
| OtezlaApremilast | 23 | $117,788 |
| Humira(Cf) PenAdalimumab | 12 | $80,028 |
| Dupixent PenDupilumab | 16 | $61,539 |
| Clobetasol Propionate | 67 | $2,908 |
| Ketoconazole | 92 | $2,185 |
| Triamcinolone Acetonide | 138 | $1,374 |
| Doxycycline Hyclate | 62 | $1,195 |
| Mometasone Furoate | 47 | $871 |
| Clindamycin Phosphate | 15 | $628 |
| Metronidazole | 12 | $609 |
| CiclopiroxCiclopirox Olamine | 14 | $587 |
| Betamethasone Valerate | 12 | $576 |
| Cephalexin | 141 | $403 |
| Minocycline Hcl | 22 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $3,054 | $285,19621 claims |
| AmgenOtezla | $588 | $117,78823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Kansas City
- Jennifer DavissonKansas City$343K
- Sileen DowisKansas City$117K
- Krishna SchmidtKansas City$18K
- Nicholas MaxwellKansas City$10K
- Megan HottelKansas City$8K
- Andrew BergLees Summit$245K
- Daniel BeckSikeston$114K
- Amee RozancO Fallon$101K
- Autumn WillsCape Girardeau$37K
- Kimberly BrownSaint Louis$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.